Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial

Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial

Ivonescimab beat Keytruda in a China Phase 3 NSCLC trial, cutting death risk 27% and extending survival.